Learn how we are raising industry quality standards by using improved technology to manufacture and validate our products.
To ensure that our antibodies are specific and provide reproducible results, we have recently introduced knockout (KO) validation at scale. Using human KO cell lines, we are developing a growing range of KO-validated antibodies, including many recombinant monoclonal antibodies.
Abcam将严格按照隐私政策处理您的个人数据点击此处。 这将包括发送您可能会感兴趣的有关Abcam的更新、我们的产品和资源的更新。您可以通过点击我们发送的每封电子邮件底部的链接来退订和管理您的营销偏好。通过此操作，您同意Abcam与您当地的授权经销商共享您的详细信息，以回答您的查询。
Dr Alejandra Solache
Dr Alejandra Solache joined Abcam in 2013 as Head of Reagents, Product Development and Manufacturing globally. She is responsible for managing the output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically new product development, core reagents and R&D. She also plays a key role in developing our innovation strategy.
